Dulaglutide(Eli Lilly) positive for hypertension effects

Dulaglutide, the long-acting glucagon-like peptide 1 (GLP-1) analog, from Eli Lilly which is being studied as a once-weekly treatment for Type 2 Diabetes, met its primary endpoint of non-inferiority for mean 24-hour systolic blood pressure (SBP, or pressure while the heart contracts) after 16 weeks. The results came from a Phase II study that compared two doses of dulaglutide to placebo, using ambulatory blood pressure monitoring to characterize changes in blood pressure and heart rate. In addition, the 1.5 mg dulaglutide dose significantly reduced mean 24-hour SBP compared to placebo. These data were presented during a late-breaking clinical trial session at the 2012 Annual Scientific Meeting of the American Society of Hypertension (ASH) in New York.